CN105980858A - 分拣蛋白作为针对情感/心境障碍的生物标记的用途 - Google Patents

分拣蛋白作为针对情感/心境障碍的生物标记的用途 Download PDF

Info

Publication number
CN105980858A
CN105980858A CN201580008112.4A CN201580008112A CN105980858A CN 105980858 A CN105980858 A CN 105980858A CN 201580008112 A CN201580008112 A CN 201580008112A CN 105980858 A CN105980858 A CN 105980858A
Authority
CN
China
Prior art keywords
experimenter
bipolar disorder
sorting protein
sorting
sortilin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580008112.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·L·耶普森
A·尼科耶尔
N·P·O·莫斯
C·M·彼得森
S·D·厄斯特高
S·格莱若普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of CN105980858A publication Critical patent/CN105980858A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580008112.4A 2014-02-12 2015-02-06 分拣蛋白作为针对情感/心境障碍的生物标记的用途 Pending CN105980858A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201400075 2014-02-12
DKPA201400075 2014-02-12
PCT/EP2015/052506 WO2015121166A1 (en) 2014-02-12 2015-02-06 Use of sortilin as biomarker for affective/mood disorders

Publications (1)

Publication Number Publication Date
CN105980858A true CN105980858A (zh) 2016-09-28

Family

ID=52462923

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580008112.4A Pending CN105980858A (zh) 2014-02-12 2015-02-06 分拣蛋白作为针对情感/心境障碍的生物标记的用途

Country Status (6)

Country Link
US (1) US20160349276A1 (enExample)
EP (1) EP3105594A1 (enExample)
JP (1) JP2017508144A (enExample)
CN (1) CN105980858A (enExample)
HK (1) HK1232289A1 (enExample)
WO (1) WO2015121166A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021185124A1 (zh) * 2020-03-18 2021-09-23 东南大学 维生素d结合蛋白作为标志物在精神疾病抑郁症诊断中的应用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849992B1 (en) 2015-04-07 2020-12-01 Alector Llc Methods of screening for sortilin binding antagonists
HUE057432T2 (hu) 2015-04-07 2022-05-28 Alector Llc Anti-sortilin antitestek és ezek alkalmazási módjai
FR3057267A1 (fr) * 2016-10-11 2018-04-13 Centre National De La Recherche Scientifique - Cnrs - Procede de diagnostic/determination de l'efficacite de traitement de la depression
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
RS64034B1 (sr) 2018-07-13 2023-04-28 Alector Llc Anti-sortilin antitela i načini njihove upotrebe

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010097631A1 (en) * 2009-02-27 2010-09-02 Cambridge Enterprise Limited Biomarkers
WO2011077129A1 (en) * 2009-12-21 2011-06-30 Cambridge Enterprise Limited Biomarkers
WO2012085555A2 (en) * 2010-12-20 2012-06-28 Cambridge Enterprise Limited Biomarkers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010069331A2 (en) * 2008-12-19 2010-06-24 H. Lundbeck A/S Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010097631A1 (en) * 2009-02-27 2010-09-02 Cambridge Enterprise Limited Biomarkers
WO2011077129A1 (en) * 2009-12-21 2011-06-30 Cambridge Enterprise Limited Biomarkers
WO2012085555A2 (en) * 2010-12-20 2012-06-28 Cambridge Enterprise Limited Biomarkers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021185124A1 (zh) * 2020-03-18 2021-09-23 东南大学 维生素d结合蛋白作为标志物在精神疾病抑郁症诊断中的应用

Also Published As

Publication number Publication date
HK1232289A1 (zh) 2018-01-05
EP3105594A1 (en) 2016-12-21
US20160349276A1 (en) 2016-12-01
JP2017508144A (ja) 2017-03-23
WO2015121166A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
CN105980858A (zh) 分拣蛋白作为针对情感/心境障碍的生物标记的用途
US20240426842A1 (en) Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
Pengo et al. Antibody profiles for the diagnosis of antiphospholipid syndrome
O’Bryant et al. A blood-based algorithm for the detection of Alzheimer’s disease
Hénault et al. Direct binding of anti–DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis
Zetterberg et al. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease
O'Bryant et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI
Suzuki et al. Three types of striational antibodies in myasthenia gravis
Wyrobek et al. Association of intraoperative changes in brain-derived neurotrophic factor and postoperative delirium in older adults
Vergallo et al. Brain Aβ load association and sexual dimorphism of plasma BACE1 concentrations in cognitively normal individuals at risk for AD
Bartosik‐Psujek et al. Total tau and S100b proteins in different types of multiple sclerosis and during immunosuppressive treatment with mitoxantrone
Sehlin et al. Interference from heterophilic antibodies in amyloid-β oligomer ELISAs
Werner et al. Antibody levels correlate with creatine kinase levels and strength in anti-HMG-CoA reductase-associated autoimmune myopathy
Liesz et al. Acquired Immunoglobulin G deficiency in stroke patients and experimental brain ischemia
Chanson et al. Evaluation of clinical interest of anti‐aquaporin‐4 autoantibody followup in neuromyelitis optica
Kollert et al. Soluble CD90 as a potential marker of pulmonary involvement in systemic sclerosis
Song et al. Serum anti-amyloid-β antibodies and Alzheimer's disease in elderly Korean patients
Catania et al. Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of Mild Cognitive Impairment by the fully automated Lumipulse® platform
EP3117218A1 (en) Novel biomarkers
JP7808340B2 (ja) 軽度認知障害検査
Tandon et al. Predictors of cognitive decline in healthy middle-aged individuals with asymptomatic Alzheimer’s disease
US20010051345A1 (en) Method for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
TWI542877B (zh) Diagnostic kit, diagnostic marker, and detection method for Alzheimer's type dementia based on sugar chain determination of complement C3 protein
CN104487847B (zh) 与阿尔茨海默氏病和轻度认知障碍相关的原肌球蛋白同种型
Abraham et al. Combined measurement of PEDF, haptoglobin and tau in cerebrospinal fluid improves the diagnostic discrimination between alzheimer’s disease and other dementias

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160928

WD01 Invention patent application deemed withdrawn after publication